Statin Drugs or Niacin - ask me no questions...

The New England Journal of Medicine published a recent study which showed that niacin (a low-cost B vitamin) out-performs Merck's drug Zetia for preventing the build-up of arterial plaque, a symptom of cardiovascular disease.

The study revealed patients taking niacin showed a "significant shrinkage" in artery wall thickness, while those on Zetia showed no such improvement. At the same time, the rate of "cardiovascular events" in the niacin group was only one-fifth that in the Zetia group, demonstrating that niacin is far more effective at preventing heart attacks and other similar events than Zetia.

But curiously, as soon as niacin started to show a real benefit over Zetia, researchers cancelled the study.

Merck, the maker of Zetia, reportedly brings in over $5 billion. It's no wonder: Zetia sells for as much as $3.89 per pill.

Niacin, on the other hand, costs as little as 6.7 cents per pill, even in a "no-flush" time-release formula.

[Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England Journal of Medicine. Published online 16 November 2009]

Other references: Merck Liver Damage? Examiner

No comments: